SOURCE: Samaritan Pharmaceuticals Inc.

June 28, 2005 09:00 ET

Samaritan Pharmaceuticals to Present at Micro Cap Conference in Las Vegas

LAS VEGAS, NV -- (MARKET WIRE) -- June 28, 2005 -- Samaritan Pharmaceuticals Inc. (AMEX: LIV), a developer of innovative drugs, announced today that it will be a featured presenter at the Cinapsys Micro cap Conference June 29th in Las Vegas, Nevada.

Dr. Greeson will introduce Samaritan as a Biotech-Pharma, with a business strategy poised to experience tremendous growth. Dr. Greeson will highlight Samaritan's most advanced drug candidates, out of its 250 identified compounds, with an emphasis on its late stage drug, SP-01A, an oral entry inhibitor HIV drug currently in PII clinical trials.

The conference will be held at the Mirage Hotel, 3400 Las Vegas Blvd. South, Las Vegas, NV, beginning at 8:00 AM PST. Samaritan will present at 2:00 PM in the Grand Ballroom G. Registration opens at 7:30 AM PST for invited guests.

The event is being sponsored by NevWest Securities, JM Dutton & Associates, Continental Stock Transfer, MarketWire, Securities Compliance Control, The SEC Law Firm,, MarketWire, the Nutmeg Group, Shelley International and other notable industry providers. Samaritan will present for 20 minutes, followed by a 10-minute question and answer session.

More details and a full schedule are available at:

About the Cinapsys Micro cap Conference

The Cinapsys Micro cap Conferences provide a concentrated forum where Institutional and retail Investors can meet and network with the executives of growth companies hand picked by Cinapsys staff. The conference will highlight approximately two dozen companies from industry groups including Health Care/Life Sciences; Consumer Products; Digital Media, High Tech and more.

Samaritan Pharmaceuticals: "A Cure Is Closer Than You Think."

Samaritan Pharmaceuticals is a drug development company driven to commercialize its pipeline of innovative drugs. Samaritan, in collaboration with Georgetown University, is currently advancing 8 innovative drugs for AIDS, Alzheimer's, Cancer and Cardiovascular disease, out of its pipeline of over 250 compounds. Samaritan has a portfolio of 3 issued patents and an additional 48 patents pending that could create numerous revenue-generating opportunities. Additional information is at


The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.

Contact Information